- Home
- GLUE vs MOV Comparison
GLUE vs MOV Comparison
Compare GLUE & MOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- MOV
- Stock Information
- Founded
- GLUE 2019
- MOV 1961
- Country
- GLUE United States
- MOV United States
- Employees
- GLUE N/A
- MOV N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- MOV Consumer Specialties
- Sector
- GLUE Health Care
- MOV Consumer Discretionary
- Exchange
- GLUE Nasdaq
- MOV Nasdaq
- Market Cap
- GLUE 351.2M
- MOV 339.1M
- IPO Year
- GLUE 2021
- MOV 1993
- Fundamental
- Price
- GLUE $4.80
- MOV $18.27
- Analyst Decision
- GLUE Buy
- MOV Strong Buy
- Analyst Count
- GLUE 2
- MOV 1
- Target Price
- GLUE $13.50
- MOV $31.50
- AVG Volume (30 Days)
- GLUE 358.2K
- MOV 140.5K
- Earning Date
- GLUE 08-07-2025
- MOV 08-28-2025
- Dividend Yield
- GLUE N/A
- MOV 7.68%
- EPS Growth
- GLUE N/A
- MOV N/A
- EPS
- GLUE 0.29
- MOV 0.77
- Revenue
- GLUE $177,986,000.00
- MOV $655,597,000.00
- Revenue This Year
- GLUE $83.76
- MOV $0.71
- Revenue Next Year
- GLUE N/A
- MOV N/A
- P/E Ratio
- GLUE $16.33
- MOV $23.13
- Revenue Growth
- GLUE 2990.57
- MOV 0.43
- 52 Week Low
- GLUE $3.50
- MOV $12.85
- 52 Week High
- GLUE $12.40
- MOV $24.47
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- MOV 70.66
- Support Level
- GLUE $4.54
- MOV $16.75
- Resistance Level
- GLUE $4.93
- MOV $17.55
- Average True Range (ATR)
- GLUE 0.21
- MOV 0.49
- MACD
- GLUE 0.06
- MOV 0.20
- Stochastic Oscillator
- GLUE 81.43
- MOV 99.42
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.